chicagoest, the final part of your post has me intrigued...An Israeli partnership is huge - RVX-208 may be marketed in Israel before the US. A safe, effective pill treatment with a successful roll-out in Israel - what better way to get the word out at the grass roots level- knowledge would quickly spread to US physicians - a brilliant marketing plan. 

A breakthrough drug, in a new area of science, if successful, I believe would be rapidly embrassed by Israel based scientists and doctors and then by investors in Israel and then New York, etc. That is my opinion.

However, I do not understand the Medison deal. I don't know what strategic framework this deal fits into.

GLTA

Toinv